GMAB Genmab - ADR

$GMAB Growing royalties, positive Phase 3 EPKINLY data and promising Rina-S results. Plenty of pipeline upside backed by an already profitable business. Added a few more. Bullish on the long-term story 😎

$GMAB Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer "today announced results from Part C of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), demonstrated that among 109 treated patients with platinum-resistant ovarian cancer (PROC), Rina-S achieved a confirmed objective response rate (ORR) of 45.9% (95% CI: 36.3–55.7), including five complete responses (CRs) and a median duration of response (mDOR) of 12.1 months (95% CI: 6.5–15.4), with 51% of responders remaining in response at one year."

$GMAB Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer Phase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) with rinatabart sesutecan (Rina-S®) compared to investigator’s choice chemotherapy Results demonstrated statistically significant and clinically meaningful improvement in PFS and OS in patients with platinum-resistant ovarian cancer (PROC) Data will be submitted for presentation at a future medical meeting and discussed with regulatory authorities worldwide

$GMAB 🏥 Genmab A/S announced positive topline results from the Phase 3 RAINFOL-02 trial showing rinatabart sesutecan met the primary progression-free survival endpoint and key secondary overall survival endpoint with statistically significant and clinically meaningful improvement versus investigator's choice chemotherapy in platinum-resistant ovarian cancer. Selected from hundreds of headlines

$GMAB headline here and wow the options Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

$GMAB Genmab's ovarian cancer drug Rina-S cut the risk of death by 57% in its first Phase 3 trial. 🏢 Genmab is a Copenhagen antibody-drug developer worth about $2.76B at $42.605 a share at 12:07 ET on October 23, 2026, whose science is behind eight approved medicines, and it earns royalties on J&J's DARZALEX, which sold $4,239M in Q3 2026 ✅ In the 584-patient Phase 3 RAINFOL-02 trial in platinum-resistant ovarian cancer, Rina-S beat chemotherapy, cutting the risk of progression or death by 71% (HR 0.29) and the risk of death by 57% (HR 0.43) ⚠️ The release gives only hazard ratios, with no median survival months, response rates or side-effect rates, the trial was open-label with investigator-assessed progression as its primary endpoint, and Rina-S is not yet approved anywhere 📅 Next: Genmab hosts an investor update on Wednesday, October 28 at 5:00 p.m. CET/12:00 p.m. EDT, and will take the data to regulators worldwide and to a future medical meeting Source: SEC 6-K, Oct 23

Genmab reported positive preliminary Phase 3 results for epcoritamab combined with R-CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL). The EPCORE DLBCL-2 trial, conducted with AbbVie, showed a statistically significant improvement in progression-free survival among patients with International Prognostic Index scores of 2–5, reducing the risk of disease progression or death by 51% (hazard ratio 0.49). The company said this is the first Phase 3 study of a bispecific-antibody combination to demonstrate such an improvement in first-line DLBCL. Epcoritamab is a subcutaneous T-cell-engaging bispecific antibody already approved in several lymphoma indications across more than 65 countries under the EPKINLY and TEPKINLY brands. Genmab and AbbVie plan to engage global regulators on next steps and present the data at a future medical meeting. The epcoritamab/R-CHOP combination remains investigational and is not yet approved. $GMAB $ABBV

$GMAB - along with $PCVX today, more of what $XBI needs for sentiment to rebound PFS win for phase 3 study in frontline DLBCL, solid HR + p-value = new SOC 👏

$GMAB Monday intraday recap. Plan posted Monday: long entry $38.16, target $38.38, stop $38.00. Thesis: 5-minute support stabilization into nearby supply, with daily higher-high / higher-low structure behind it. Status: Closed — target hit Monday, banked the same session. I am no longer in it. Trading around $39.25 this morning (Tue, verified). Just the plan, posted before and after — no guarantees.

$GMAB Genmab presented the Phase 2 Rina-S data at today's IGCS late-breaking session: 45.9% confirmed response rate in platinum-resistant ovarian cancer (109 patients), five complete responses. Durability holds up underneath: median response duration 12.1 months, half of responders still in response at one year, median PFS 9.5 months. The biology line is what stands out: activity regardless of FRa expression, including low expressors and non-expressors, and regardless of prior mirvetuximab. Rina-S was the lead asset when Genmab paid 1.8 billion dollars for ProfoundBio in May 2024. Four Phase 3 trials are now running.